HistoRx Expand its Senior Management Team
News Feb 02, 2006
HistoRx, Inc. has announced the expansion of its senior management team in order to advance the development and commercialization of the Company's first series of molecular diagnostic tests based on the AQUA™ platform.
HistoRx has added three industry leaders with extensive experience in the production and commercialization of protein biomarker discovery and diagnostic products.
The new additions represent a significant increase in the company's effort to advance personalized medicine by stratifying patients and tailoring therapeutic regimes through improved predictive diagnostics.
The new team includes, Donna Marino, vice president of Diagnostics, Lorah Perlee, Ph.D, vice president of Technical Operations, and Robert Tuttle, M.Phil., director of Bioinformatics.
"Building upon the strong uptake of the AQUA™ quantitative pathology platform, this new team will accelerate the commercialization of our pipeline of molecular diagnostic tests with the launch of our first product in early 2008," noted Dr. Robert A. Curtis, president and chief executive officer of HistoRx.
"Additionally in 2006, we plan to significantly expand upon our current pharmaceutical collaborations as well as seek additional partnerships to advance our product and technology development."
The Company has been developing a portfolio of tissue-based molecular tests. The new management will focus on prioritization, development, and commercialization of the tests on the AQUA™ platform.
The AQUA™ platform is designed to represent the first integrated automated fluorescence-based imaging platform to identify and quantitate tissue biomarkers in high throughput tissue microarray format or in whole tissue slices.
The AQUA™ platform measures changes in expression levels of multiple protein biomarkers at the subcellular level while maintaining the spatial relationship between the targets of interest.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.